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Vasopressin receptor-mediated endocytosis in cells transfected with
V1-type vasopressin receptors. We examined the process of receptor-
mediated endocytosis in A-9 lung fibroblast and chinese hamster ovary
(CHO) cells transfected with the recently cloned vasopressin Via
receptor (51). We used a fluorescent labeled vasopressin analog (rho-
damine-mercaptopropionic acid lysine vasopressin) and radiolabeled
vasopressin to examine this process in the two transfected cell lines.
Both A-9 and CHO cells internalize vasopressin in a manner consistent
with receptor-mediated endocytosis. A-9 cells internalize vasopressin
more rapidly than CHO cells. The process is inhibited by vasopressin
and by specific vasopressin V1 receptor antagonists but not by specific
V2 receptor antagonists. Hypertonic sucrose inhibits endocytosis in
both cell types suggesting a role of clathrin coated pits in the endocy-
tosis of receptor in these cells. These cells are excellent models in
which to examine the effect of receptor mutations on vasopressin
receptor-mediated endocytosis.
The process of receptor-mediated endocytosis (RME) is
involved in the uptake of nutrients such as: iron, cholesterol,
and vitellogenin [1—3]; the clearance of certain serum proteins
targeted for degradation such as protease-c2-macroglobuIin
complexes and asialaglycoproteins [4, 5]; the acquisition of
maternal immunoglobulins by the fetus and neonate [6, 7];
antigen processing by lymphocytes [8—10]; and the uptake of
growth factors and hormones [11—13]. In addition, certain
viruses may pirate the RME pathway to gain entry into host
cells [14, 15].
The role of RME in the action of growth factors and hor-
mones is less apparent than for the other types of participants
listed above. RME may modulate cell responsiveness by caus-
ing the loss of growth factor or hormone receptors from the cell
surface such that cryptic receptors are no longer accessible,
making cells less responsive to a subsequent ligand challenge
[16—19]. Furthermore, RME may limit the initial response of
cells to growth factors or hormones by removing activated
receptors from access to the second messenger system of the
cell [20]. The expression of cloned full-length, truncated or
mutant receptors holds great potential for identifying and es-
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tablishing the function of the molecular components of RME
and for understanding the role of RME in growth factor and
hormone action. The use of these methods has given insight into
the structural aspects of hormone receptors that are important
for their participation in RME [2 1—271. Also, site-directed
mutagenesis and cell transfection of hormone and growth factor
receptors has been used to probe the involvement of RME in
the cellular response to growth factors and hormones [28—33].
Vasopressin, a cyclic nonapeptide, functions to control
plasma osmolality and water metabolism by regulating urine
concentration and alters the tone of certain vascular beds
[34-36]. The physiological effects of vasopressin are mediated
by two types of cell surface receptors that are distinguished by
their affinity for various vasopressin analogs and by the second
messenger systems they activate. 1a type vasopressin recep-
tors are found in vascular smooth cells, hepatocytes, platelets,
and mesangial cells in the glomerulus [37—42]. Vasopressin
activation of ViatYPC receptors results in the formation of
inositol I ,4,5-triphosphate and diacyiglycerol, which increase
intracellular Ca2 and protein kinase C activity. V2-type vaso-
pressin receptors are found in polarized epithelial cells of the
distal nephron of the kidney and in granular cells of the
amphibian bladder. Vasopressin activation of V2-type receptors
stimulates adenylate cyclase, increasing intracellular adenosine
3' ,5'-cyclic monophosphate (cAMP) content which activates
various protein kinases. We and others have demonstrated that
vasopressin receptors upon binding vasopressin are internal-
ized into cells by RME [41, 43—49]. Recently, we have made
observations that indicate vasopressin RME may limit the
initial response of cells to vasopressin by eliminating access of
receptors to the second messenger system [50]. The Via-type
vasopressin receptor has recently been cloned and expressed in
cells which normally do not express the protein [51]. The study
of RME in cells expressing the cloned vasopressin receptor, or
a mutant thereof, should yield important insights into the
physiology of the vasopressin receptor. The present study was
performed to determine the basic aspects of vasopressin RME
in two cell lines transfected with the cloned V1-type vasopres-
sin receptor. We show that vasopressin RME occurs in a
manner analogous to that observed in cells normally expressing
the Via type receptor. These results establish these transfected
cells as model systems for the study of vasopressin RME by
molecular biological methods.
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Methods
8-Arginine vasopressin (AVP), [d(CH2)5 D-11e2,11e4,Arg8]-
vasopressin, and [1 -(f3-mercapto-f3, /3-cyclopentamethylene pro-
pionic acid), 2-(O-methyl) tyrosine]-Arg8-vasopressin were ob-
tained from Peninsula Laboratories, Inc. (Belmont, California,
USA). [3H]AVP (60.4 Cilmmol) was obtained from Dupont-
New England Nuclear (Wilmington, Delaware, USA). [1-(2-
mercapto) propionic acid] -8-ly sine-N6-carboxytetramethyl-
rhodamine vasopressin (R-MLVP) was prepared by coupling
5- and 6-carboxytetramethylrhodamine (succinimidyl ester);
(Molecular Probes Inc., Eugene, Oregon, USA) to [l-(2-mer-
capto) propionic acid]-8-lysine vasopressin (MLVP) by the
method described previously [46]. MLVP was synthesized by
the Merrifield solid-phase method.
Cell culture procedures
A9 F5-36 and CHO C8-36 cell lines were prepared by
transfecting A-9 cells and CHO K! cells (ATCC No. CCLG1),
respectively, with the V1-type vasopressin receptor as previ-
ously described [51]. These cells displayed the appropriate
biological response to vasopressin V1 agonists [51]. CHO C8-36
and CHO Kl cells were grown as a monolayer in 75 cm2
polystyrene culture flasks (Corning Glass Works, Corning, New
York, USA) using a Minimum Essential Medium (aMEM);
(GIBCO-BRL, Gaithersburg, Maryland, USA) supplemented
with 10% (vol/vol) fetal bovine serum plus 100 U/mi penicillin
and 100 zgIml streptomycin in a humified incubator at 37°C
using a 95% air, 5% CO2 atmosphere. Confluent cells were
subcultured by treatment with a phosphate-buffered saline
(PBS) trypsin-EDTA solution (0,25% trypsin, 0.25% EDTA).
CHO C8-36 cells to be used for determining AVP binding and
internalization were subcultured into 12 well culture trays at 1.5
to 2.0 x i04 cells per well and used at confluency (3 to 4 days).
CHO cells used for epifluorescence microscopy were seeded in
24-well culture trays containing circular glass microscope coy-
erslips (12 mm in diameter; Fischer Scientific, Pittsburgh,
Pennsylvania, USA) at a density of 1.2 x l0 cells per well and
used three days later.
A-9 F5-36 and A-9 cells were grown as a monolayer in 75 cm2
polystyrene culture flasks (Corning Glass Works) using Dulbec-
co's modification of Eagle's medium (DMEM) (GIBCO-BRL)
supplemented with 10% (vollvol) fetal bovine serum plus 100
U/ml penicillin and 100 g/ml streptomycin. Confluent cells
were subcultured by treatment of the cell monolayer with
PBS-trypsin-EDTA solution (0.25% trypsin, 0.25% EDTA). A-9
F5-36 cells to be used for determining AVP binding and
internalization were subcultured into 12-well culture trays at 3
to 3.5 x i04 cells per well and used at confluency (3 to 4 days).
A-9 F5-36 cells used for epifluorescence microscopy were
seeded in 24-well culture trays containing circular glass micro-
scope coverslips (12 mm diameter, Fischer Scientific) at a
density of 2.5 x i04 cells per well and used three days later.
A-9 and CHO cells in culture trays were counted in a
hemocytometer after being lifted by trypsin treatment and
suspension in culture medium.
Epjfluorescence microscopy
Fluorescence microscopy experiments were conducted with
A-9 and CHO cells cultured in monolayer on circular glass
microscope coverslips in 24-well culture trays as described
above. Culture trays were placed on ice, growth medium was
removed, and wells washed three times with 1 ml of ice-cold
serum-free aMEM culture medium for CHO cells and ice-cold
serum-free DMEM culture medium for A-9 cells. Cells were
then exposed to R-MLVP without or with AVP (2 M) in
serum-free culture medium at 4°C for one hour. Cells were then
incubated further for various time periods at 37°C in the
presence of incubation medium preheated to 37°C containing
R-MLVP. When used, AVP, was also present during the 37°C
incubation period. Incubation periods were terminated by re-
moving the incubation medium and rinsing the cells with a 2%
solution of para-formaldehyde in PBS (pH 7.4) containing 1 mti
MgC12 and 0.8 mtvi CaCl2 (PBS/MgCl2/CaC12). Cells were fixed
in the same solution for one hour at room temperature. After
rinsing with PBS/MgCl2/CaCI2 the coverslips were mounted on
microscope slides with Airvol (Air Products, Allentown, Penn-
sylvania, USA) mountant containing 2% n-propyl gallate, pH>
8.0 [52].
Mounted cells were observed using a Nikon FXA microscope
(Fryer Co., Inc., Carpertersville, Iffinois, USA) equipped for
epifluorescence and photographed using a 60x/1.4 n.a. plan apo
objective and recorded on Hypertech Film (Microfluor, Ltd.,
Stony Brook, New York) at an ASA setting of 1600 (8 to 12
second exposure).
Vasopressin binding and internalization
Vasopressin receptor-specific binding and internalization of
[3H]AVP were determined in A-9 and CHO cells grown in
monolayer in 12-well culture trays as described above. Culture
trays were floated in a 37°C water bath, the culture medium was
removed, and the cells were washed twice with serum-free
culture medium (1 mlIwell), (aMEM for CHO cells and DMEM
for A-9 cells) preheated to 37°C. Cells were then incubated with
[3H]AVP (3 nM) in serum-free culture medium (pH 7.4) with or
without 2 /.LM AVP. To determine the effect of hypertonicity on
the binding and internalization of AVP, cells were incubated in
serum-free culture medium without or with 0.4 M sucrose for 30
minutes at 37°C prior to exposure to [3H]AVP (3 nM). Exposure
to [3HIAVP was in incubation medium of the same composition
as was present during the preincubation period (that is, if
sucrose was present during the preincubation period, it was also
present during incubation with [3H]AVP) with or without 2 /LM
AVP. At the times indicated culture trays containing triplicate
wells were placed on ice, the incubation medium was removed
and the cells were washed three times with 2 ml ice-cold PBS
(pH 7.4) containing 1 m MgCl2, 0.8 m'vi CaC12 and bovine
serum albumin (0.1% wt/vol). Radioactivity bound to the sur-
face of cells was eluted by incubating cells with 0.5 ml of an
ice-cold buffer containing 0.2 M acetic acid (pH 3.0), and 0.5 M
NaC1 for five minutes according to the method of Haigler et al
[531. Cells were washed with an additional 0.5 ml of ice-cold
buffer containing 0.2 M acetic acid (pH 3.0), and 0.5 M NaCL.
Radioactivity in the combined acid washes was counted and
considered to represent surface-associated radioactivity. Ra-
dioactivity remaining (within the cells) after acid treatment was
solubilized with 1% (wt/voi) sodium dodecyl sulfate and was
considered to represent internalized radioactivity. Receptor
specific surface-associated and internalized radioactivity was
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Fig. 1. [3HJAVP binding and internalization by CHO cells. Trans-
fected and untransfected CHO cells grown in 12-well culture plates
were incubated with [3HIAVP (3 nM) with or without 2 M AVP as
described in Methods. At the indicated times receptor specific surface
associated (0 transfected) and internalized radioactivity (• transfected)
were determined according to the procedures as described. Values are
expressed as DPM per well (triplicate determinations, mean SD).
Wells seeded at the same density contained 1.02 x 106 6.7 >( io
cells per well. Untransfected cells exhibited no surface binding or
internalization.
recorded as the difference in radioactivity measured in the
presence and absence of non-radiolabeled AVP (2 tiM),
Scatchard analysis was performed at 4°C with A-9 and CR0
cells as described previously [46].
Results
Vasopressin binding and internalization
Transfected CHO and A-9 cells grown in monolayer in
12-well culture plates were incubated with [3H]AVP (3 nM) at
37°C and receptor specific surface associated and internalized
radioactivity were determined at the indicated times (Figs. 1
and 2). In transfected CR0 cells receptor specific surface
associated radioactivity increased to a maximum after 25 min-
utes and then declined during the remainder of the incubation
period (Fig. 1). The rate of decrease in surface associated
radioactivity was slower during the last 60 minutes. Internalized
radioactivity increased steadily, reaching a peak at 25 minutes
and then declined towards a steady state during the next 35
minutes (Fig. 1). In transfected A-9 cells receptor-specific
surface-associated radioactivity increased rapidly peaking after
only five minutes of exposure to [3HIAVP, followed by a rapid
decline during the next 20 minutes (Fig. 2). Surface associated
radioactivity declined slowly during the remainder of the incu-
bation period. Changes in receptor specific internalized radio-
activity in A-9 cells paralleled changes in surface associated
radioactivity (Fig. 2). Internalized radioactivity peaked after 10
minutes, decreased rapidly during the next 15 minutes, followed
by a slow rate of decrease during the remainder of the incuba-
tion period. Non-specific binding was less than 10% of total
binding and did not change with time. Untransfected CHO and
A-9 cells exhibited no vasopressin receptor specific binding and
internalization of [3H]AVP.
Time, minutes
Fig. 2. [3HJAVP binding and internalization by A-9 cells. Transfected
and untransfected CHO cells grown in 12-well culture plates were
incubated with 3H]AVP (3 nM) with or without 2 M AVP as described
in Methods. At the indicated times receptor specific surface associated
(0 transfected) and internalized radioactivity (• transfected) were deter-
mined according to the procedures described. Values are expressed as
DPM per well (triplicate determinations, mean SD). Wells seeded at the
same density contained 8.3 x IO 5.4 x iO cells per well. Untransfected
cells exhibited no surface binding or internalization.
To confirm the vasopressin receptor subtype mediating the
binding and internalization of [3HIAVP by CHO and A-9 cells
the ability of V1 and V2 specific vasopressin antagonists to
inhibit the binding and internalization of [3H]AVP was as-
sessed. The antagonist [l-(f3-mercapto-J3,13-cyclopentameth-
ylene propionic acid) 2-(0-methyl) tyrosinel-Arg8-vasopressin
[54] was as effective as nonradiolabeled AVP in inhibiting the
binding and internalization of [3HIAVP by CHO cells (Fig. 3)
and A-9 cells (Fig. 4), whereas the V2 antagonist [d(CH2)5,
D-Ile2, lie4, Arg8]-vasopressin [55] was ineffective in inhibiting
the binding and internalization of {3HIAVP by CR0 cells (Fig.
3) and A-9 cells (Fig. 4).
The effect of hypertonicity on the binding and internalization
of [3H]AVP was assessed by preincubating CHO and A-9 cells
in serum-free culture medium without or with 0.4 M sucrose,
followed by exposure to [3H]AVP (3 flM) for 15 minutes in
medium of the same composition. In both cells types, hyper-
tonic treatment inhibited receptor specific internalization of
[3H]AVP (Figs. 5 and 6). As a consequence of the inhibition of
receptor-mediated internalization of [3H]AVP, surface associ-
ated [3H]AVP was increased (Figs. 5 and 6).
Scatchard analysis of [3H]AVP binding at 4°C indicated that
transfected A-9 cells contained 40,000 receptors per cell or less,
whereas transfected CR0 cells contained 225,000 receptors per
cell.
Internalization of R-MLVP
A rhodamine-labeled derivative of vasopressin (R-MLVP)
was used to visualize the receptor specific uptake and intracel-
lular localization of vasopressin by transfected CHO and A-9
cells grown in monolayer on circular glass microscope cover-
slips. Cells were incubated with R-MLVP for one hour at 4°C.
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Fig. 3. Effect of vasopressin and V1 and V2 vasopressin analogs on
12 H]A VP binding and internalization by transfected CHO cells. Cells
grown in 12-well culture plates were incubated with [3H]AVP (3 nM)
without (LI) or with AVP (U, 0.5 /LM), or with the V1 antagonist,
[1-()3-mercapto-/3,j3-cyclopentamethylene propionic acid) 2-(O-methyl)
tyrosine]-Arg8-vasopressin (, 0.05 M; 111,0.1 jM; and U, 0.5 /SM), or
with the V2 antagonist, [4(CH2)5, D-11e2, lie4, Arg8]-vasopressin (0,
0.05 ,LM; , 0.1 and ll, 0.5 rM) for 15 minutes at 37°C. Surface
associated and internalized radioactivity were determined according to
the procedures described in the Methods. Values are expressed as
means SD of triplicate determinations.
Surface Internal
Location
Fig. 4. Effect of vasopressin and V1 and V2 vasopressin analogs on
[3H]AVP binding and internalization by transfected A-9 cells. Cells
grown in 12-well culture plates were incubated with [3H]AVP (3 nM)
without (LI) or with AVP (U, 0.5 MM); or with the V1 antagonist,
[1-(f3-mercapto-f3,/3-cyclopentamethylene propionic acid) 2-(O-methyl)
tyrosine]-Arg8-vasopressin (Z, 0.05 j.M; , 0.1 and , 0.5 tM), or
with the V2 antagonist, [d(CH2)5, D-Ile2, lie4, Arg8]-vasopressin (,
0.05 ILM; , 0.1 and lL:, 0.5 tM) for 15 minutes at 37°C. Surface
associated and internalized radioactivity were determined according to
the procedures described in Methods. Values are expressed as means
SD of triplicate determinations.
This preincubation period allowed binding of R-MLVP to cell
surface vasopressin receptors in the absence of ligand-receptor
complex internalization which is inhibited at 4°C. Upon warm-
ing to 37°C, the endocytic pathway becomes active, resulting in
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Fig. 5. Effect of hypertonicity on 12 HIA VP binding and internalization
by transfected CHO cells. Transfected CHO cells grown in 12-well
culture plates were incubated without (U) or with () 0.4 M sucrose in
serum-free culture medium for 30 minutes at 37°C followed by incuba-
tion with [3HIAVP (3 nM) with or without 2 M AVP for 15 minutes;
Receptor specific surface-associated and internalized radioactivity were
determined according to the procedures described in the Methods.
Values are expressed as DPM per well (triplicate determinations, mean
SD).
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Fig. 6. Effect of hypertonicity on 12 HIA VP binding and internalization
by transfected A-9 cells. Transfected A-9 cells grown in 12-well culture
plates were incubated without (U) or with () 0.4 M sucrose in
serum-free culture medium for 30 minutes at 37°C followed by incuba-
tion with [3H]AVP (3 nM) with or without 2 M AVP for 15 minutes.
Receptor specific surface associated and internalized radioactivity were
determined according to the procedures described in the Methods.
Values are expressed as DPM per well (triplicate determinations, mean
SD).
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the internalization of the ligand-receptor complex, which can be
visualized by epifluorescence microscopy. Cell associated flu-
orescence was observed by monitoring the rhodamine excita-
tion-emission of washed and fixed cells as described above. In
CR0 cells, diffuse surface associated fluorescence was ob-
served at the end of the preincubation period. Punctate areas of
fluorescence appeared in the cytoplasm with incubation at 37°C
'—
4 
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Fig. 7. Visualization of R-MLVP binding and internalization by transfected CHO cells. Cells grown in monolayer on glass coverslips were
incubated with 4 M R-MLVP with or without 2 tM AVP for 60 minutes at 4°C followed by incubation at 37°C in the presence of R-MLVP for 0,
prior to warmup (A); 20 (B); 60 (C); 90 (D); 120 (E); 60, with 2 M AVP (F) minutes. Scale bar = 5 m.
(Fig. 7). Upon further incubation, the areas of punctate fluo-
rescence increased in size and intensity and concentrated in a
perinuclear position within the cell. At the end of the preincu-
bation period, transfected A-9 cells displayed diffuse fluores-
cence on the surface (Fig. 8). After warming to 37°C in the
continued presence of the fluorescent vasopressin analog an
array of punctate areas of fluorescence was observed in the
cytoplasm of A-9 cells. With further incubation at 37°C punctate
areas of fluorescence increased in size and intensity and tended
to distribute in a perinuclear position within the cell. The time
course of changes in the distribution of punctate fluorescence in
CHO cells is slower than observed in A-9 cells. The vasopressin
receptor specificity of the pattern of punctate fluorescence
observed in both cell types was indicated by the inhibition of
the formation of the punctate fluorescence in the presence of an
excess of AVP.
Discussion
Analysis of the structure and function of a number of cell
surface receptors has been greatly facilitated by the cloning of
their cDNAs. The recent cloning of the cDNA for the Ia
vasopressin receptor and its transfection into cells that do not
normally express the protein offers an opportunity to study the
structure and function of this receptor. In this communication
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Fig. 8. Visualization of R-ML VP binding and internalization by transftctedA-9 cells. Cells grown in monolayer on glass coverslips were incubated
with 200 nM R-MLVP with or without 2 sM AVP for 60 minutes at 4°C followed by incubation at 37°C in the presence of R-MLVP for 0, prior to
warmup (A); 20 (B); 60 (C); and 60, with 2 sM AVP (D) minutes. Scale bar = 5 m.
we present the results of experiments investigating the appro-
priateness of CHO and A-9 cells transfected with the Via
vasopressin receptor as model systems for study of vasopressin
receptor-mediated endocytosis.
Transfected CHO and A-9 cells bound and internalized
[3H]AVP in a vasopressin receptor-specific manner. The inhi-
bition of [3H]AVP binding and internalization in both cell types
by a V1 antagonist and not by a V2 antagonist indicates RME
occurs via the V1 type vasopressin receptor. A-9 cells ex-
pressed fewer receptors on their surface than CHO cells as
indicated by lower levels of bound and internalized [3H]AVP
with similar number of cells per well (Figs. 1 and 2). This
difference in receptor density probably accounts, in part, for the
ability of A-9 cells to reach peak levels of bound and internal-
ized [3H]AVP more quickly. Hypertonic treatment inhibited the
receptor-specific internalization of [3H]AVP and resulted in an
increase in receptor-specific surface associated [3H]AVP in
both cell types. This observation suggests, but does not prove,
that vasopressin RME is occurring in these cells by a clathrin-
coated pit-mediated process as hypertonicity has been shown to
inhibit the formation of clathrin coated pits on the surface of
cells [56]. We cannot, however, exclude the possibility that
hypertonic sucrose effects processes other than clathrin medi-
ated RME that may directly influence RME. The inhibition of
vasopressin RME by hypertonicity in these transfected cells is
similar to the inhibition recently observed in A-b cells, a
vascular smooth muscle cell line which expresses Via type
vasopressin receptors, and in LLC-PK1 cells, a kidney epithe-
hal cell line which expresses V2 type vasopressin receptors [50].
The cellular distribution pattern in A-9 and CHO cells sug-
gests that R-MLVP is being distributed to a region of the cell
that is likely to be Golgi apparatus and the lysosome compart-
ment. It should be emphasized that although the images suggest
this location, we did not use specific methods to identify these
compartments. The endocytic pathway indicated by these ob-
servations is similar to the pathway observed in LLC-PK1 cells
which express the V2 type vasopressin receptor [46, 47]. The
endocytic pathway observed in CHO and A-9 cells likely results
from the endocytic machinery of these cell types as Via type
vasopressin receptors in A- 10 cells appear to utilize a different
endocytic pathway [46, 47].
The results of this study indicate that vasopressin RME
occurs in CHO and A-9 cells transfected with the Via vasopres-
sin receptors in a manner similar to that observed in cells which
normally express vasopressin receptors. These observations
establish these cells as model systems in which the structural
and functional aspects of vasopressin RME can be studied using
mutant receptors prepared by site-directed mutagenesis.
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